Is it Working? Imaging the Immune Response in Melanoma

14 March 2019

Traditional imaging – such as MRIs or CAT scans – provide insight into the effectiveness of immunotherapy by measuring tumor size. While this works, some patients may take months to respond to immunotherapy and in other cases, tumors may appear to actually grow on these scans, falsely indicating progression.

Read More


How Jaqueline’s Promise and Persistence Paid Off

5 March 2019 In Melanoma Stories

Melanoma wasn't supposed to happen to Jacqueline. Melanoma was supposed to be a disease that older, white women got, not 21-year-old African Americans. "People often think having more melanin makes them from developing melanoma. But they’re wrong,” Jacqueline says.

Read More


Fight Back Give Back with Clinical Trials

By Cody R. Barnett, MRA Director of Communications | 24 February 2019 In News, Science

When patients understand all of their options, including clinical trials, they can make informed decisions about their care. For many patients, clinical trials represent the best possible way to get access to cutting-edge treatment options.

Read More


Overcoming Targeted Therapy Resistance

By Marc Hurlbert, Ph.D., MRA Chief Science Officer | 22 February 2019 In Science, Treatment

Targeted therapies work well for many patients, but most will go on to develop acquired resistance. Researchers are working to address this challenge. Learn about two promising examples.

Read More


It’s Not that Simple: Young Women and Melanoma

By Cody R. Barnett, MRA Director of Communications | 15 February 2019 In Prevention, Science

Article after article describes the ‘skyrocketing’ increases in melanoma among young women. While most are quick to point out the clear association between intentional tanning and skin cancer, few ever hint that there may be more to the story.

Read More


Doing Good in Rebecca's Name

7 February 2019 In Melanoma Stories

It was March of 2005 when Christine Garrison’s life changed forever. She received the phone call that no mother ever wants to receive. Her daughter Rebecca’s suspicious mole was, in fact, Stage 3 melanoma.

Read More


UV4Me Reaches Young Adults About Sun Safety

By Cody R. Barnett, MRA Director of Communications | 1 February 2019 In Allies & Partnerships, Prevention

Among young people, rates of melanoma are especially alarming. It is now the second most-common cancer among young women aged 20 – 29. While many programs focus specifically on children, studies suggest that we receive over half of our lifetime exposure to UV after the age of 20. Yet, few evidence-based programs focus specifically on the needs of young adults.

Read More


Unchartered Territory: When Should Patients Stop Immunotherapy?

By Cody R. Barnett, MRA Director of Communications | 23 January 2019 In Melanoma Stories, Science, Treatment

For melanoma patients, deciding when to discontinue treatment is a difficult decision. should the general ‘rule of thumb’ of treating patients with advanced disease until progression still apply? In the absence of definitive data – what does indirect data tell us?

Read More


Melanoma Treatment Advances – 2018 in Review

By Marc Hurlbert, Ph.D., MRA Chief Science Officer | 18 January 2019 In Science, Treatment

2018 brought new and expanded drug approvals that give patients, doctors, and their families more treatment options with fewer side effects. Learn more about important melanoma treatment advances in 2018.

Read More


From Health Scare to Transformative Change

By Cody R. Barnett, MRA Director of Communications | 16 January 2019 In Melanoma Stories

Debra Black founded the Melanoma Research Alliance in 2007 after her own diagnosis with Stage II disease earlier that year. Since then, MRA has become the largest, non-profit funder of melanoma research worldwide.

Read More


Login

×